Ones To Watch News
Refine Search
Biotechnology
ImmunityBio lost 54% of its market value on Thursday. 12 May 2023
Biotechnology
Shares in Texan pharma company Reata Pharmaceuticals closed 15% lower on Wednesday. 11 May 2023
Biotechnology
Shares in Novavax, a US company advancing protein-based vaccines with its Matrix-M adjuvant, have increased by more than a quarter so far this week. 11 May 2023
Biotechnology
Austria-based DNA synthesis specialist Ribbon Biolabs has appointed Jodi Barrientos as chief business officer. 11 May 2023
Biotechnology
UK-based cancer immunotherapy company Immodulon has named Richard Davies its new chairman of the board, appointed Gertjan Bartlema chief executive and brought in Peter Greaney as chief business officer. 10 May 2023
Biotechnology
Shares of UK biotech Bicycle Therapeutics rode up 8.6% to $24.30 by mid-morning US trading, on the news of a potentially lucrative deal with Germany’s Bayer. 10 May 2023
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, has reached an agreement to acquire CTI BioPharma, a US biopharma company focused on blood related cancers and rare diseases, by means of a tender offer. 10 May 2023
Biotechnology
Cell programming and biosecurity platform company Ginkgo Bioworks has announced a new partnership with privately-held German pharma major Boehringer Ingelheim. 10 May 2023
Biotechnology
US biopharma Insmed yesterday announced progress across its early-stage research programs, at the company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More. 10 May 2023
Biotechnology
The UK’s biggest drugmaker, AstraZeneca, has terminated a collaboration with oncolytic virus company Transgene. 5 May 2023
Biotechnology
US antibody-drug conjugate (ADC) specialist ImmunoGen closed 123% higher after trading on Wednesday. 4 May 2023
Biotechnology
The announcement earlier this week of Japanese pharm major Astellas Pharma $5.9 billion acquisition of US biotech Iveric Bio has prompted a speedy evaluation comment from GlobalData pharma analyst Prashant Khadayate. 3 May 2023
Pharmaceutical
The Franco-Israeli partnership of MedinCell and Teva Pharmaceutical Industries has announced today that the US Food and Drug Administration (FDA) has approved Uzedy (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. 2 May 2023
Biotechnology
Shares of Danish biotech Ascendis Pharma leapt, despite the company revealing that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the TransCon PTH (palopegteriparatide) New Drug Application (NDA) for the treatment of adults with hypoparathyroidism. 2 May 2023
Biotechnology
Maze Therapeutics, a privately-held Californian company translating genetic insights into new precision medicines, has announced the signing of an exclusive worldwide license agreement with French pharma major Sanofi. 2 May 2023
Biotechnology
Shares of New Jersey, USA-based biotech firm Iveric Bio closed up nearly 16% at $38.05 yesterday, on the news of an agreed takeover bid from Japanese pharma major Astellas Pharma, with the latter rising 2.2% to 2,093 yen. 2 May 2023
Biotechnology
USA-based Nanoscope Therapeutics, a biotech developing gene therapies for retinal degenerative diseases, has presented results from the Phase IIb RESTORE trial of MCO-010 for the treatment of retinitis pigmentosa at the ARVO Annual Meeting. 2 May 2023
Pharmaceutical
A 12% jump in the stock price of Avadel Pharmaceuticals on Monday reflects market confidence in the firm’s newly-approved cataplexy med Lumryz (sodium oxybate). 2 May 2023
Pharmaceutical
As a next step in focusing on the US market, the board of Swedish diagnostic testing and precision medicines firm Immunovia AB has decided to appoint Jeff Borcherding, until now president of Immunovia’s US operation, as global chief executive 2 May 2023
Biotechnology
Nektar Therapeutics has announced that it will be regaining the full rights to rezpegaldesleukin (REZPEG; NKTR-358) from Eli Lilly (NYSE: LLY) which concludes the two companies’ collaboration that begun in 2017. 28 April 2023
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze